BRPI0509979A - método para detectar ncrna - Google Patents

método para detectar ncrna

Info

Publication number
BRPI0509979A
BRPI0509979A BRPI0509979-0A BRPI0509979A BRPI0509979A BR PI0509979 A BRPI0509979 A BR PI0509979A BR PI0509979 A BRPI0509979 A BR PI0509979A BR PI0509979 A BRPI0509979 A BR PI0509979A
Authority
BR
Brazil
Prior art keywords
ncrna
detecting
purposes
detect
signature
Prior art date
Application number
BRPI0509979-0A
Other languages
English (en)
Inventor
Jian Han
Original Assignee
Genaco Biomedical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaco Biomedical Products Inc filed Critical Genaco Biomedical Products Inc
Publication of BRPI0509979A publication Critical patent/BRPI0509979A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/101—Modifications characterised by incorporating non-naturally occurring nucleotides, e.g. inosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/107—Temperature of melting, i.e. Tm
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

MéTODO PARA DETECTAR ncRNA é descrito um novo método para a detecção de moléculas de ncRNA. O método divulgado é especialmente útil para a detecção de miRNA e siRNA. O método pode ser usado para gerar um perfil das moléculas de ncRNA presentes em uma amostra. Além disso, usando os métodos da presente divulgação pode ser criada uma assinatura de ncRNA para uma dada doença ou condição. A assinatura de ncRNA pode ser usada para finalidades diagnósticas, finalidades terapêuticas e finalidade de descobrimento de drogas, assim como para outros usos.
BRPI0509979-0A 2004-04-20 2005-04-20 método para detectar ncrna BRPI0509979A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56387704P 2004-04-20 2004-04-20
PCT/US2005/013247 WO2005103298A2 (en) 2004-04-20 2005-04-20 Method for detecting ncrna

Publications (1)

Publication Number Publication Date
BRPI0509979A true BRPI0509979A (pt) 2007-10-16

Family

ID=35197559

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509979-0A BRPI0509979A (pt) 2004-04-20 2005-04-20 método para detectar ncrna

Country Status (10)

Country Link
US (1) US7811759B2 (pt)
EP (1) EP1745150A4 (pt)
JP (1) JP2007533324A (pt)
KR (1) KR20070004957A (pt)
CN (1) CN101056991A (pt)
AU (1) AU2005236044B2 (pt)
BR (1) BRPI0509979A (pt)
CA (1) CA2585525A1 (pt)
NZ (1) NZ551019A (pt)
WO (1) WO2005103298A2 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP1877557A2 (en) 2005-04-04 2008-01-16 The Board of Regents of The University of Texas System Micro-rna's that regulate muscle cells
US20060247503A1 (en) * 2005-04-29 2006-11-02 Sellers Orlando Ii Method for predicting a transition to an increased probability of injury
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
JP2007082436A (ja) * 2005-09-20 2007-04-05 Bioinformatics Institute For Global Good Inc 機能性ＲＮＡが制御するターゲットｍＲＮＡの予測・同定方法及びその利用方法
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
EP1969147B1 (en) * 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
US7955848B2 (en) 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
AU2012216487B2 (en) * 2006-04-03 2015-05-14 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8207325B2 (en) 2006-04-03 2012-06-26 Univ. of Copenhagen MicroRNA biomarkers for human breast and lung cancer
EP2041317A4 (en) 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
US20080081330A1 (en) * 2006-09-28 2008-04-03 Helicos Biosciences Corporation Method and devices for analyzing small RNA molecules
WO2008052774A2 (en) * 2006-10-31 2008-05-08 Noxxon Pharma Ag Methods for detection of a single- or double-stranded nucleic acid molecule
US8252538B2 (en) * 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008071384A1 (en) * 2006-12-13 2008-06-19 Roche Diagnostics Gmbh Use of tde for the isolation of nucleic acids
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
CA2716906A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2265291B1 (en) 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
US9347089B2 (en) * 2008-09-19 2016-05-24 Children's Medical Center Corporation Therapeutic and diagnostic strategies
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
US20110117559A1 (en) * 2009-11-13 2011-05-19 Integrated Dna Technologies, Inc. Small rna detection assays
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
ES2986436T3 (es) 2011-04-15 2024-11-11 Univ Johns Hopkins Sistema de secuenciación segura
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
JP6146760B2 (ja) * 2012-02-28 2017-06-14 国立研究開発法人産業技術総合研究所 序列化装置、序列化方法及びプログラム
WO2013153911A1 (ja) * 2012-04-12 2013-10-17 国立大学法人東京大学 核酸の定量方法、検出プローブ、検出プローブセット、及び核酸の検出方法
CN103146688B (zh) * 2012-09-12 2015-05-13 上海长海医院 长链非编码rna作为疾病诊断血液分子标志物的应用
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
US20160024565A1 (en) * 2013-03-13 2016-01-28 Tufts University Fragment complementation of based assays
JP2017511694A (ja) * 2014-02-12 2017-04-27 トーマス・ジェファーソン・ユニバーシティ マイクロｒｎａ阻害剤を使用するための組成物および方法
EP2949759B1 (en) 2014-05-27 2017-07-26 Université Paris Sud 11 Multiplexed homogeneous oligonucleotide detection
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
AU2017372695B2 (en) * 2016-12-05 2023-07-20 Regulus Therapeutics Inc. Methods for treatment of polycystic kidney disease
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
US20220275455A1 (en) * 2019-07-08 2022-09-01 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease
EP4103748A4 (en) 2020-02-14 2024-03-13 The Johns Hopkins University METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS
WO2023060237A1 (en) 2021-10-08 2023-04-13 Regulus Therapeutics Inc. Methods and compositions for treatment of polycystic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988617A (en) * 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
JPH06502766A (ja) * 1990-11-14 1994-03-31 アクゾ・ノベル・ナムローゼ・フェンノートシャップ ポリスチレン支持体ベース−サンドイッチハイブリダイゼーションアッセイ法を用いる核酸の非同位体検出およびそれに用いる組成物
AU9240898A (en) * 1997-07-04 1999-01-25 Gist-Brocades B.V. Process for the modification of toxic and/or off-flavoured compounds
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
WO2001013119A1 (en) * 1999-08-17 2001-02-22 Luminex Corporation Encapsulation of fluorescent particles
WO2002012263A1 (en) * 2000-08-03 2002-02-14 Roche Diagnostics Gmbh Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP4537053B2 (ja) * 2001-06-25 2010-09-01 ジョージア テック リサーチ コーポレーション 二重共鳴エネルギー転移核酸プローブ
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20050042623A1 (en) * 2002-10-30 2005-02-24 Dana Ault-Riche Systems for capture and analysis of biological particles and methods using the systems
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features

Also Published As

Publication number Publication date
AU2005236044A1 (en) 2005-11-03
US7811759B2 (en) 2010-10-12
EP1745150A2 (en) 2007-01-24
WO2005103298A2 (en) 2005-11-03
CN101056991A (zh) 2007-10-17
JP2007533324A (ja) 2007-11-22
WO2005103298A9 (en) 2007-05-18
WO2005103298A3 (en) 2005-12-15
EP1745150A4 (en) 2008-02-27
AU2005236044B2 (en) 2010-01-07
NZ551019A (en) 2009-08-28
CA2585525A1 (en) 2005-11-03
US20080166707A1 (en) 2008-07-10
KR20070004957A (ko) 2007-01-09

Similar Documents

Publication Publication Date Title
BRPI0509979A (pt) método para detectar ncrna
BRPI0906858B8 (pt) métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer.
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112015030287A2 (pt) ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas
CY1114111T1 (el) Μεθοδοι χρησης του mirna για την ανιχνευση του in vivo θανατου των κυτταρων
EP4219760A3 (en) Methods, compositions, and devices utilizing microrna to determine physiological conditions
BR112015001038A2 (pt) método e sistema para indicar hiperglicemia ou hipoglicemia para pessoas com diabetes
BRPI0906261A2 (pt) "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
BR112015026601A2 (pt) método para um ensaio de triagem de fármaco à base de células e o uso do mesmo
BRPI0917871A2 (pt) agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
EP3239305A3 (en) Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
DOP2011000045A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
BRPI0922650A2 (pt) Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
BR112014011818A2 (pt) método para realizar ensaios de quantificação
BR112013008573A2 (pt) citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
BR112013023970A2 (pt) composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
BRPI0714563B8 (pt) métodos para detectar a pré-disposição à ou estágio de um câncer em um indivíduo mamífero, para triagem, identificação ou otimização de um medicamento anti-câncer, para modificação de um gene de mamífero in vitro e para avaliação da eficácia de um medicamento anti-câncer ou medicamento candidato
BRPI1008936B8 (pt) método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano
EA201401353A1 (ru) Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк)
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
BR112014029808A2 (pt) método para testar o efeito de uma etapa de produção ou etapas de produção ou a eficácia de uma etapa de purificação ou etapas de purificação na presença ou na natureza de moléculas pró-inflamatórias em polímeros de glicose ou hidrolisados dos mesmos; e método otimizado para produzir ou purificar polímeros de glicose ou hidrolisados dos mesmos
FI20095187A7 (fi) Menetelmä ja laitteisto etanolin tunnistusta varten

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.